On July 24, CMBC CAPITAL fell 13.16% in regular trading, trading at HKD 3.17/share, with turnover of HKD 34.39 million. The stock has been under sustained heavy selling pressure since July 21.

On the news front, Puqi Pharmaceutical's Hong Kong IPO prospectus officially expired on July 21, with CMBC CAPITAL serving as one of the joint sponsors. The company previously reported annual net profit growth of 197.73% to HKD 151 million, driven primarily by a significant increase in securities underwriting and sponsorship fee income. The failure to advance the sponsored project has triggered persistent market concerns over the sustainability of its core business revenue stream. Additionally, southbound capital has been continuously reducing positions in recent sessions, intensifying short-term selling pressure. A brief rebound on July 22 failed to hold, with the stock resuming its decline on July 23 before extending losses further today.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)